Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
186 studies found for:    "Eye Diseases, Hereditary" OR "Peters plus syndrome"
Show Display Options
Download search resultsDownload the search results for:
"Eye Diseases, Hereditary" OR "Peters plus syndrome" (186 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Active, not recruiting Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa
Conditions: Retinitis Pigmentosa;   Retinal Diseases;   Eye Diseases;   Eye Disease, Hereditary;   Retinal Degeneration
Intervention: Drug: Valproic Acid
2 Recruiting Doxycycline Treatment in Mild Graves' Orbitopathy
Conditions: Graves Ophthalmopathy;   Graves Disease;   Eye Diseases;   Thyroid Diseases;   Endocrine System Diseases;   Eye Diseases, Hereditary;   Hyperthyroidism;   Autoimmune Diseases;   Immune System Diseases
Interventions: Drug: Doxycycline;   Drug: placebo
3 Completed Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
Conditions: Graves Ophthalmopathy;   Graves Disease;   Eye Diseases;   Thyroid Diseases;   Endocrine System Diseases;   Eye Diseases, Hereditary;   Hyperthyroidism;   Autoimmune Diseases;   Immune System Diseases
Intervention: Drug: Doxycycline
4 Completed Fundus Changes in the Microphthalmy Eyes
Condition: Eye Diseases, Hereditary
Intervention:
5 Completed Screening for Studies on Inherited Eye Diseases
Condition: Hereditary Eye Disease
Intervention:
6 Completed Evaluation and Treatment of Patients With Inherited Eye Diseases
Condition: Hereditary Eye Disease
Intervention:
7 Withdrawn Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD
Conditions: Choroidal Neovascularization;   Myopia;   Punctate Inner Choroidopathy (PIC);   Multifocal Choroiditis;   Ocular Histoplasmosis Syndrome;   Central Serous Chorioretinopathy (CSC);   Angioid Streaks;   Trauma, or Hereditary Eye Diseases
Interventions: Drug: Bevacizumab (Avastin; Genentech, Inc.);   Drug: Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy
8 Recruiting Congenital Muscle Disease Study of Patient and Family Reported Medical Information
Conditions: Muscular Dystrophy;   Congenital Muscular Dystrophy;   Fukutin-related Protein Gene;   Limb Girdle;   FKRP Gene;   Childhood Onset LGMD;   Adult Onset LGMD;   POMT1;   POMT2;   POMGnT1;   LARGE;   Alpha Dystroglycan;   Dystroglycanopathy;   Centronuclear;   Multiminicore;   Multicore;   Minicore;   Congenital Fiber Type Disproportion;   Myotubular;   Nemaline;   Congenital Myopathy;   Neuromuscular;   Rigid Spine;   Phenotype-Genotype Correlation;   Cough Assisted Device;   Neuromuscular Disease;   Respiratory Exacerbation;   Invasive Ventilation;   Chest Physiotherapy;   Congenital Myopathies;   Genetic Mutations;   Hypertrophic Cardiomyopathy;   Wheelchair Use;   Cataract;   Opthalmoplegia;   Ullrich Congenital Muscular Dystrophy;   Intermediate Collagen VI Myopathy;   Laminin Alpha 2 Related Congenital Muscular Dystrophy;   MDC1A;   Merosin Deficient Congenital Muscular Dystrophy;   Congenital Muscular Dystrophy Undiagnosed;   Congenital Muscular Dystrophy Merosin Positive;   Walker Warburg Syndrome;   Muscle Eye Brain Disease;   Fukuyama;   Integrin Alpha 7 Deficiency;   Integrin Alpha 9 Deficiency;   Laminopathy;   Lamin AC;   SEPN 1 Related Myopathies;   Bethlem Myopathy;   Dystroglycanopathies;   LGMD2K;   LGMD2I;   LGMD2L;   LGMD2N;   Actin Aggregation Myopathy;   Cap Disease;   Central Core Disease;   Centronuclear Myopathy;   Core Rod Myopathy;   Hyaline Body Myopathy;   Multiminicore Myopathy;   Myotubular Myopathy;   Nemaline Myopathy;   Tubular Aggregate Myopathy;   Zebra Body Disease Myopathy;   Congenital Myopathy Other;   Reducing Body Myopathy;   Sarcotubular Myopathy;   Spheroid Body Myopathy
Intervention:
9 Recruiting Safety and Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients
Conditions: Retinitis Pigmentosa;   Retinal Degeneration
Intervention: Device: Device name: "Retina Implant model Alpha". Surgical implantation of medical device into eye
10 Completed Treatment of Congenital Stationary Night Blindness With an Alga Containing High Dose of Beta Carotene
Condition: Night Blindness
Intervention: Dietary Supplement: alga Dunaliella bardawil
11 Completed Autosomal Dominant Retinitis Pigmentosa: Prevalence of Known Genes Identification of New Loci / Genes
Condition: Autosomal Dominant Retinitis Pigmentosa
Intervention: Genetic: genetic analysis
12 Enrolling by invitation Using the Optovue OCT to Select IOL Power
Conditions: Fuchs' Endothelial Dystrophy;   Cataract
Intervention:
13 Completed Evaluation of Objective Perimetry Using Pupillometer
Conditions: Retinitis Pigmentosa;   Glaucoma;   Visual Field
Intervention:
14 Withdrawn Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome
Conditions: Hermanski-Pudlak Syndrome;   Colitis;   Cytokines;   Lymphocytes;   Drug Evaluation
Interventions: Drug: Mesalamine;   Drug: Infliximab;   Drug: Corticosteroids;   Drug: 6-Mercaptopurine;   Drug: Tacrolimus;   Drug: Adalimumab
15 Recruiting New Enrollment Post-Approval Study of the Argus® II Retinal Prosthesis System
Condition: Retinitis Pigmentosa
Intervention:
16 Not yet recruiting The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa
Condition: Retinitis Pigmentosa
Interventions: Dietary Supplement: Alga Dunaliella Bardawil powder;   Dietary Supplement: Placebo:Starch
17 Recruiting The Molecular Pathogenesis of Late-onset Fuchs' Endothelial Corneal Dystrophy
Condition: Fuchs' Endothelial Dystrophy
Intervention: Other: No intervention
18 Completed Study of the Correlation Between Macular Thickness Analyzed by Optical Coherence Tomography and the Visual Functions in Retinitis Pigmemtosa
Condition: Retinitis Pigmentosa
Intervention:
19 Completed Transcorneal Electrostimulation for Therapy of Retinitis Pigmentosa
Condition: Retinitis Pigmentosa
Intervention: Device: transcorneal electrostimulation
20 Active, not recruiting DHA and X-Linked Retinitis Pigmentosa
Conditions: Retinitis Pigmentosa;   X-linked Genetic Diseases
Intervention: Drug: docosahexaenoic acid OR corn/soy oil placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years